Hull and East Yorkshire Hospitals NHS Trust
Hull, East Yorkshire, HU3 2JZ, United Kingdom
NCT Number: NCT03295630
This study will determine whether an Actigraph GT3X accelerometer can identify body position and quantify step count in a ward based population recovering from critical illness.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Hull, East Yorkshire, HU3 2JZ, United Kingdom
Ward based patients recovering from critical illness who satisfy the inclusion criteria will have an Actigraph GT3X accelerometer positioned on the thigh and ankle of the non dominant leg. These will be used as an objective method of identifying adoption of lying, sitting and standing postures and quantification of step count. Both placement sites will be investigated in isolation. A further analysis will be undertaken to determine whether combining data from both placement sites (ankle and thigh) is superior in identification of lying, sitting and standing postures compared to an isolated single site. Accelerometer data will be compared against direct observation as the criterion measure.
Patients will undertake a semi-structured movement protocol consisting of typical activities undertaken by this population. These include lying in bed, transferring over the side of the bed, sit to stand postural transfers (and the reverse), sitting in a chair and walking. Observation periods will not exceed 3 hours. During this time all aspects of the movement protocol will be completed.
The data from this study will be analysed to determine the validity of the Actigraph GT3X in identification of body position and quantification of step count using the placement sites described above.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
1 18 years of age or above.
Exclusion criteria
Participants will perform a semi-structured movement protocol to investigate the ability of the Actigraph GT3X accelerometer to identify body position (lying, sitting or standing) and quantify step count.
Time frame: Participants wore the accelerometers for a maximum of 3 hours, undertaking a semi-structured movement protocol
Agreement between direct observation and the activity monitors (ankle and thigh placements in isolation) in determination of step count. The mean difference (95% Limits of Agreement) between observed step count and accelerometer quantified step count for the same walk were calculated. Negative values reflected an underestimation of observed step count by the accelerometer and positive values reflected an overestimation of step count.
Time frame: Accelerometers were worn for a period not exceeding 3 hours
Participants were asked to rate their assessment of how comfortable the accelerometers were. They were requested to choose a statement on a five-point Likert Scale. The statements were:
Participants chose the most appropriate statement which they felt reflected how comfortable they found the accelerometers to wear.
Hull University Teaching Hospitals NHS Trust
Other Gov
Criterion Validity of the Actigraph GT3X Accelerometer in Determination of Body Position and Walking in Hospital Ward Patients Recovering From Critical Illness
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03628300
Acute Kidney Injury, Beta Lactams
Amiens, France
View Trial DetailsNCT05960994
Critical Care, Intensive Care Units
São Paulo, Brazil
View Trial DetailsNCT05937646
Behavior, Communication
Chapel Hill, North Carolina, United States
View Trial DetailsNCT03683329
Cancer, Critical Care
Marseille, France
View Trial Details